Research and Development

We are actively developing innovative approaches to deliver affordable, safe, and effective CAR T-cell therapies, aiming to significantly reduce treatment costs while maintaining the highest standards of quality and efficacy.

Novelty and Advancement over Current State-of-the-Art

Current State-of-the-Art (Problem):

USFDA-approved anti-FMC63CAR-T cell therapies — Breyanzi, Tecartus, Yescarta, and Kymriah utilize the FMC63-derived anti-FMC63CAR construct incorporating CD28/4-1BB-CD3ζ signaling domains. These constructs feature only one cation-π interaction with the human CD19 antigen, enabling recognition of CD19 isoforms 1–7 and 9.However, CD19 isoforms 8 and 10 escape recognition, leading to antigen escape–mediated relapse in treated patients.

Similarly ,an Indian ImmunoACT NexCAR19, featuring two cation–π interactions, improves recognition to cover isoforms 1–7 and 9–10, but still fails to target isoform 8, leaving room for antigen escape.

Proposed Solution — LYSINE BIOTECH Innovation:

The Indian Lysine Biotech huanti-CD19 CAR-CD27/4-1BB-CD3ζ construct introduces six distinct cation-π interactions, enabling comprehensive recognition of all ten human CD19 antigen isoforms (1–10).

Novel Features:

Pan-isoform targeting: No CD19 antigen isoform escape.

Enhanced binding affinity and specificity toward human CD19 antigen.

Reduced relapse potential due to elimination of antigen escape variants.

Improved therapeutic efficacy and persistence through incorporation of CD3zeta Single ITAM Activating T cell and CD27, and 4-1BB costimulatory domains.

Intellectual Property: Lysine Biotech Private Limited, USPTO Published Patent No.: 8/897,292 (USPTO Application No.: US 20250250316 A1) and Indian Patent Granted No.: 567126 (Application Number:.202341064804).

Read More About Products R&D Pipline

3.A patent is published in the USA (USPTO) and granted in India

1)Patent Title: Design and Composition of HuAnti-CD19 Chimeric Antigen Receptor Targeting B-Cell Malignancies Thereof

U.S. Patent No.: 8,897,292, U.S. Patent Application Number: US 2025/0250316 A1, Publication Date: August 7, 2025.Global Dossier.

2).Patent Title: Design and Composition of HuAnti-CD19 Chimeric Antigen Receptor Targeting B-Cell Malignancies Thereof

Indian Patent Granted No.: 567126, Indian Patent Application Number: 202341064804, Date of Issue: June 3, 2025.ipindia.gov.in.

3).Patent Title: DESIGN AND COMPOSITION OF LYSILIRAG-1 (GLP-1) DRUG FOR TREATING TYPE-2 DIABETES IN OBESE THEREOF

Indian Patent Application IN 202441008291 (Patent Examination Submitted Jan.15th 2026 and Hearing on 02.March 2026)ipindia.gov.in.

4).Patent Title: DESIGN AND COMPOSITION OF SYNTHETIC PEPTIDE DRUG TO INHIBIT BETA-SECRETASE CLEAVAGE OF AMYLOID-BETA PRECURSOR PROTEIN THEREOF

Indian Patent Application IN 202441028428 (Patent Publication date 12/04/2024 and Request for Examination & Date 19-12-2025)ipindia.gov.in.

5).Patent Title: DESIGN AND COMPOSITION OF OLIGONUCLEOTIDES PRIMER SEQUENCES FOR DIAGNOSIS OF LEPTOSPIRA INTERROGANS AND APPLICATION FOR MRNA BASED HUMAN AND VETERINARY VACCINE AGAINST LEPTOSPIROSIS THEREOF

Indian Patent Application IN 202441031814 (Patent Publication date 26/04/2024)ipindia.gov.in.